Newsfeeds - Spark Newswire

1 minute read

ALX Oncology Holdings Q2 EPS $(0.40) Down From $(0.22) YoY, Adj. Net Loss $14.037M vs Loss $10.698M In Same Qtr. Last Year

Today, 4:18 AM

ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.40) per share. This is a 81.82 percent decrease over losses of $(0.22) per share from the same period last year.

ALXO

3 minute read

Why Odonate Therapeutics, Opthea, ALX Oncology, Advaxis and Provention Bio Are Moving Today

By Shanthi Rexaline

Today, 4:18 AM

Odonate Therapeutics, Inc. (NASDAQ: ODT), Opthea Limited (NASDAQ: OPT), ALX Oncology Holdings Inc.

ADXS

1 minute read

ALX Oncology Shares Jump As ALX148 Shows ORR of 72% In Patients With HER2 Positive Stomach Cancer

By Vandana Singh

Today, 4:18 AM

ALX Oncology Holdings Inc (NASDAQ:ALXO) announced updated data from its ongoing ASPEN-01 Phase 1b trial evaluating ALX148 in combination with trastuzumab…

ALXO

1 minute read

News

ALX Oncology On Saturday Announced New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer

By Benzinga Newsdesk

Today, 4:18 AM

-- ORR of 72% Observed in Patients with >2L HER2 Positive Gastric or Gastroesophageal Junction Cancer -- Estimated OS at 12 months of 76% -- ALX Oncology to Host Conference Call on

ALXO

4 minute read

The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus

By Shanthi Rexaline

Today, 4:18 AM

Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment.

AFMD

2 minute read

News

ALX Oncology Announces Update on ASPEN-03 and ASPEN-04, the ALX148 Phase 2 Head and Neck Cancer Studies

By Benzinga Newsdesk

Today, 4:18 AM

--Interim report completed by ALX for a standard ongoing non-clinical safety study --Based on the safety study results, the FDA has lifted a previously set partial clinical hold and cap on patient enrollment in

ALXO